TGFβ1 inhibits Ca2+-calcineurin-mediated activation in thymocytes

Journal of Immunology

Volumn 170, Issue 7, 2003, Pages 3645-3652

  Bommireddy, Ramireddy ^a   Ormsby, Ilona ^a   Yin, Moying ^a   Boivin, Gregory P ^a   Babcock, George F ^a,b   Doetschman, Thomas ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CALCIUM; EGTAZIC ACID; IONOMYCIN; PHORBOL 13 ACETATE 12 MYRISTATE; RECEPTOR; T LYMPHOCYTE RECEPTOR; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; AUTOIMMUNE DISEASE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL ACTIVATION; CELL DIFFERENTIATION; HOMEOSTASIS; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR INTERACTION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; THYMOCYTE;

EID: 0037378732     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.7.3645     Document Type: Article

References (69)

1. Massague, J. 2000. How cells read TGF-β signals. Nat. Rev. Mol. Cell Biol. 1:169.
2. Barnard, J. A., R. M. Lyons, and H. L. Moses. 1990. The cell biology of transforming growth factor β. Biochim. Biophys. Acta 1032:79.
3. Roberts, A. B., and M. B. Sporn. 1990. The transforming growth factor βs. In Peptide Growth Factors and Their Receptors: Handbook of Experimental Pathology. M. B. Sporn and A. B. Roberts, eds. Springer-Verlag, Heidelberg, p. 419.
4. Wahl, S. M., J. M. Orenstein, and W. Chen. 2000. TGF-β influences the life and death decisions of T lymphocytes. Cytokine Growth Factor Rev. 11:71.
5. Letterio, J. J. 2000. Murine models define the role of TGF-β as a master regulator of immune cell function. Cytokine Growth Factor Rev. 11:81.
6. Kallapur, S., I. Ormsby, and T. Doetschman. 1999. Strain dependency of TGFβ1 function during embryogenesis. Mol. Reprod. Dev. 52:341.
7. Dickson, M. C., J. S. Martin, F. M. Cousins, A. B. Kulkarni, S. Karlsson, and R. J. Akhurst. 1995. Defective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice. Development 121:1845.
8. D'Souza, R. N., A. Cavender, D. Dickinson, A. Roberts, and J. Letterio. 1998. TGF-β1 is essential for the homeostasis of the dentin-pulp complex. Eur. J. Oral Sci. 106(Suppl. 1):185.
9. Glick, A. B., M. M. Lee, N. Darwiche, A. B. Kulkarni, S. Karlsson, and S. H. Yuspa. 1994. Targeted deletion of the TGF-β1 gene causes rapid progression to squamous cell carcinoma. Genes Dev. 8:2429.
10. 1 arrest, p53, and Rb. Cancer Res. 56:3645.
11. Hoying, J. B., M. Yin, R. Diebold, I. Ormsby, A. Becker, and T. Doetschman. 1999. Transforming growth factor β1 enhances platelet aggregation through a non-transcriptional effect on the fibrinogen receptor. J. Biol. Chem. 274:31008.
12. Cui, W., D. J. Fowlis, S. Bryson, E. Duffie, H. Ireland, A. Balmain, and R. J. Akhurst. 1996. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86:531.
13. Tang, B., E. P. Bottinger, S. B. Jakowlew, K. M. Bagnall, J. Mariano, M. R. Anver, J. J. Letterio, and L. M. Wakefield. 1998. Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency. Nat. Med. 4:802.
14. Engle, S. J., J. B. Hoying, G. P. Boivin, I. Ormsby, P. S. Gartside, and T. Doetschman. 1999. Transforming growth factor β1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res. 59:3379.
15. Shull, M. M., I. Ormsby, A. B. Kier, S. Pawlowski, R. J. Diebold, M. Yin, R. Allen, C. Sidman, G. Proetzel, D. Calvin, and T. Doetschman. 1992. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359:693.
16. Kulkarni, A. B., C. G. Huh, D. Becker, A. Geiser, M. Lyght, K. C. Flanders, A. B. Roberts, M. B. Sporn, J. M. Ward, and S. Karlsson. 1993. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA 90:770.
17. Teng, Y. T., R. M. Gorczynski, and N. Hozumi. 1998. The function of TGF-β-mediated innocent bystander suppression associated with physiological self-tolerance in vivo. Cell. Immunol. 190:51.
18. Khoury, S. J., W. W. Hancock, and H. L. Weiner. 1992. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 176:1355.
19. Barone, K. S., D. D. Tolarova, I. Ormsby, T. Doetschman, and J. G. Michael. 1998. Induction of oral tolerance in TGF-β1 null mice. J. Immunol. 161:154.
20. Thorbecke, G. J., D. T. Umetsu, R. H. deKruyff, G. Hansen, L. Z. Chen, and G. M. Hochwald. 2000. When engineered to produce latent TGF-β1, antigen specific T cells down regulate Th1 cell-mediated autoimmune and Th2 cell-mediated allergic inflammatory processes. Cytokine Growth Factor Rev. 11:89.
21. Gilbert, K. M., M. Thoman, K. Bauche, T. Pham, and W. O. Weigle. 1997. Transforming growth factor-β1 induces antigen-specific unresponsiveness in naive T cells. Immunol. Invest. 26:459.
22. Kitani, A., K. Chua, K. Nakamura, and W. Strober. 2000. Activated self-MHC-reactive T cells have the cytokine phenotype of Th3/T regulatory cell 1 T cells. J. Immunol. 165:691.
23. Prud'homme, G. J., and C. A. Piccirillo. 2000. The inhibitory effects of transforming growth factor-β-1 (TGF-β1) in autoimmune diseases. J. Autoimmun. 14:23.
24. Miller, A., O. Lider, A. B. Roberts, M. B. Sporn, and H. L. Weiner. 1992. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor β after antigen-specific triggering. Proc. Natl. Acad. Sci. USA 89:421.
25. Lucas, C., L. N. Bald, B. M. Fendly, M. Mora-Worms, I. S. Figari, E. J. Patzer, and M. A. Palladino. 1990. The autocrine production of transforming growth factor-β1 during lymphocyte activation: a study with a monoclonal antibody-based ELISA. J. Immunol. 145:1415.
26. + T cells. J. Exp. Med. 188:1849.
27. Chen, W., W. Jin, H. Tian, P. Sicurello, M. Frank, J. M. Orenstein, and S. M. Wahl. 2001. Requirement for transforming growth factor β1 in controlling T cell apoptosis. J. Exp. Med. 194:439.
28. Plum, J., M. De Smedt, G. Leclercq, and B. Vandekerckhove. 1995. Influence of TGF-β on murine thymocyte development in fetal thymus organ culture. J. Immunol. 154:5789.
29. Schiott, A., H. O. Sjogren, and M. Lindvall. 1998. The three isoforms of transforming growth factor-β co-stimulate rat T cells and inhibit lymphocyte apoptosis. Scand. J. Immunol. 48:371.
30. Chung, E. J., S. H. Choi, Y. H. Shim, Y. J. Bang, K. C. Hur, and C. W. Kim. 2000. Transforming growth factor-β induces apoptosis in activated murine T cells through the activation of caspase 1-like protease. Cell. Immunol. 204:46.
31. Diebold, R. J., M. J. Eis, M. Yin, I. Ormsby, G. P. Boivin, B. J. Darrow, J. E. Saffitz, and T. Doetschman. 1995. Early-onset multifocal inflammation in the transforming growth factor β1-null mouse is lymphocyte mediated. Proc. Natl. Acad. Sci. USA 92:12215.
32. Hines, K. L., A. B. Kulkarni, J. B. McCarthy, H. Tian, J. M. Ward, M. Christ, N. L. McCartney-Francis, L. T. Furcht, S. Karlsson, and S. M. Wahl. 1994. Synthetic fibronectin peptides interrupt inflammatory cell infiltration in transforming growth factor β1 knockout mice. Proc. Natl. Acad. Sci. USA 91:5187.
33. Schultz, J. J., S. A. Witt, B. J. Glascock, M. L. Nieman, P. J. Reiser, S. L. Nix, T. R. Kimball, and T. Doetschman. 2002. TGFβ1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J. Clin. Invest. 109:787.
34. Gorelik, L., and R. A. Flavell. 2000. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12:171.
35. Lucas, P. J., S. J. Kim, S. J. Melby, and R. E. Gress. 2000. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor β II receptor. J. Exp. Med. 191:1187.
36. Gorelik, L., P. E. Fields, and R. A. Flavell. 2000. Cutting edge: TGF-β inhibits Th type 2 development through inhibition of GATA-3 expression. J. Immunol. 165:4773.
37. Gorham, J. D., J. T. Lin, J. L. Sung, L. A. Rudner, and M. A. French. 2001. Genetic regulation of autoimmune disease: BALB/c background TGF-β1-deficient mice develop necroinflammatory IFN-γ-dependent hepatitis. J. Immunol. 166:6413.
38. 2-microglobulin-deficient background ameliorates lethal phenotype of the TGF-β1 null mouse. J. Immunol. 163:4013.
39. Boivin, G. P., B. A. O'Toole, I. E. Orsmby, R. J. Diebold, M. J. Eis, T. Doetschman, and A. B. Kier. 1995. Onset and progression of pathological lesions in transforming growth factor-β1-deficient mice. Am. J. Pathol. 146:276.
40. Takahama, Y., and H. Nakauchi. 1996. Phorbol ester and calcium ionophore can replace TCR signals that induce positive selection of CD4 T cells. J. Immunol. 157:1508.
41. Truneh, A., F. Albert, P. Golstein, and A. M. Schmitt-Verhulst. 1985. Early steps of lymphocyte activation bypassed by synergy between calcium ionophores and phorbol ester. Nature 313:318.
42. Chiang, Y. J., H. K. Kole, K. Brown, M. Naramura, S. Fukuhara, R. J. Hu, I. K. Jang, J. S. Gutkind, E. Shevach, and H. Gu. 2000. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403:216.
43. Davey, G. M., S. L. Schober, B. T. Endrizzi, A. K. Dutcher, S. C. Jameson, and K. A. Hogquist. 1998. Preselection thymocytes are more sensitive to T cell receptor stimulation than mature T cells. J. Exp. Med. 188:1867.
44. Lin, C. S., R. C. Boltz, J. J. Siekierka, and N. H. Sigal. 1991. FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. Cell. Immunol. 133:269.
45. Boulougouris, G., J. D. McLeod, Y. I. Patel, C. N. Ellwood, L. S. Walker, and D. M. Sansom. 1999. IL-2-independent activation and proliferation in human T cells induced by CD28. J. Immunol. 163:1809.
46. Anderson, S. J., and C. Coleclough. 1993. Regulation of CD4 and CD8 expression on mouse T cells: active removal from the cell surface by two mechanisms. J. Immunol. 151:5123.
47. Wang, T., B. Y. Li, P. D. Danielson, P. C. Shah, S. Rockwell, R. J. Lechleider, J. Martin, T. Manganaro, and P. K. Donahoe. 1996. The immunophilin FKBP12 functions as a common inhibitor of the TGF β family type 1 receptors. Cell 86:435.
48. Cameron, A. M., F. C. J. Nucifora, E. T. Fung, D. J. Livingston, R. A. Aldape, C. A. Ross, and S. H. Snyder. 1997. FKBP12 binds the inositol 1,4,5-trisphosphate receptor at leucine-proline (1400-1401) and anchors calcineurin to this FK506-like domain. J. Biol. Chem. 272:27582.
49. Cameron, A. M., J. P. Steiner, D. M. Sabatini, A. I. Kaplin, L. D. Walensky, and S. H. Snyder. 1995. Immunophilin FK506 binding protein associated with inositol 1,4,5-trisphosphate receptor modulates calcium flux. Proc. Natl. Acad. Sci. USA 92:1784.
50. 2+ flux. Cell 83:463.
51. Shou, W., B. Aghdasi, D. L. Armstrong, Q. Guo, S. Bao, M. J. Charng, L. M. Mathews, M. D. Schneider, S. L. Hamilton, and M. M. Matzuk. 1998. Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12. Nature 391:489.
52. Sanford, L. P., I. Ormsby, G. A. Gittenberger-de, H. Sariola, R. Friedman, G. P. Boivin, E. L. Cardell, and T. Doetschman. 1997. TGFβ2 knockout mice have multiple developmental defects that are non-overlapping with other TGFβ knockout phenotypes. Development 124:2659.
53. Aghdasi, B., K. Ye, A. Resnick, A. Huang, H. C. Ha, X. Guo, T. M. Dawson, V. L. Dawson, and S. H. Snyder. 2001. FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle. Proc. Natl. Acad. Sci. USA 98:2425.
54. Bassing, C. H., W. Shou, S. Muir, J. Heitman, M. M. Matzuk, and X. F. Wang. 1998. FKBP12 is not required for the modulation of transforming growth factor β receptor I signaling activity in embryonic fibroblasts and thymocytes. Cell Growth Differ. 9:223.
55. Xu, X., B. Su, R. J. Barndt, H. Chen, H. Xin, G. Yan, L. Chen, D. Cheng, J. Heitman, Y. Zhuang, S. Fleischer, and W. Shou. 2002. FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506. Transplantation 73:1835.
56. Xin, H. B., T. Senbonmatsu, D. S. Cheng, Y. X. Wang, J. A. Copello, G. J. Ji, M. L. Collier, K. Y. Deng, L. H. Jeyakumar, M. A. Magnuson, et al. 2002. Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy. Nature 416:334.
57. Yamazaki, T., H. Arase, S. Ono, H. Ohno, H. Watanabe, and T. Saito. 1997. A shift from negative to positive selection of autoreactive T cells by the reduced level of TCR signal in TCR-transgenic CD3 ζ-deficient mice. J. Immunol. 158:1634.
58. Demetriou, M., M. Granovsky, S. Quaggin, and J. W. Dennis. 2001. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 409:733.
59. Gong, Q., A. M. Cheng, A. M. Akk, J. Alberola-Ila, G. Gong, T. Pawson, and A. C. Chan. 2001. Disruption of T cell signaling networks and development by Grb2 haploid insufficiency. Nat. Immun. 2:29.
60. Bonomo, A., P. J. Kehn, and E. M. Shevach. 1994. Premature escape of doublepositive thymocytes to the periphery of young mice: possible role in autoimmunity. J. Immunol. 152:1509.
61. Tanchot, C., F. A. Lemonnier, B. Perarnau, A. A. Freitas, and B. Rocha. 1997. Differential requirements for survival and proliferation of CD8 naive or memory T cells. Science 276:2057.
62. Haskard, D., D. Cavender, and M. Ziff. 1986. Phorbol ester-stimulated T lymphocytes show enhanced adhesion to human endothelial cell monolayers. J. Immunol. 137:1429.
63. Gamble, J. R., and M. A. Vadas. 1988. Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-β. Science 242:97.
64. Gamble, J. R., and M. A. Vadas. 1991. Endothelial cell adhesiveness for human T lymphocytes is inhibited by transforming growth factor-β1. J. Immunol. 146:1149.
65. Shevach, E. M. 2000. Regulatory T cells in autoimmmunity. Annu. Rev. Immunol. 18:423.
66. + T cells secreting transforming growth factor-β1 by altered peptide ligands expressed as self-antigens. Int. Immunol. 14:857.
67. Rose, N. R., A. Herskowitz, D. A. Neumann, and N. Neu. 1988. Autoimmune myocarditis: a paradigm of post-infection autoimmune disease. Immunol. Today 9:117.
68. Yang, X., J. J. Letterio, R. J. Lechleider, L. Chen. R. Hayman, H. Gu, A. B. Roberts, and C. Deng. 1999. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β. EMBO J. 18:1280.
69. Dong, Y., L. Tang, J. J. Letterio, and E. N. Benveniste. 2001. The Smad3 protein is involved in TGF-β inhibition of class II transactivator and class II MHC expression. J. Immunol. 167:311.